{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T21:53:29Z","timestamp":1778536409621,"version":"3.51.4"},"reference-count":24,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009447","name":"Leukemia and Lymphoma Society of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009812","name":"Princess Margaret Cancer Foundation","doi-asserted-by":"publisher","award":["886199001122"],"award-info":[{"award-number":["886199001122"]}],"id":[{"id":"10.13039\/100009812","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0777-8","type":"journal-article","created":{"date-parts":[[2019,12,19]],"date-time":"2019-12-19T16:03:14Z","timestamp":1576771394000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Interleukin-15 in cancer immunotherapy: IL-15 receptor complex versus soluble IL-15 in a cancer cell-delivered murine leukemia model"],"prefix":"10.1136","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6044-6616","authenticated-orcid":false,"given":"Alexandra","family":"Berger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah J.","family":"Colpitts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie S. S.","family":"Seabrook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caren L.","family":"Furlonger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maura B.","family":"Bendix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua M.","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William M.","family":"McKillop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey A.","family":"Medin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Paige","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,12,19]]},"reference":[{"issue":"4","key":"777_CR1","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.3390\/cancers3043856","volume":"3","author":"S Lee","year":"2011","unstructured":"Lee S, Margolin K. Cytokines in cancer immunotherapy. Cancers (Basel). 2011;3(4):3856\u201393.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"777_CR2","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1053\/j.seminoncol.2015.05.015","volume":"42","author":"T Floros","year":"2015","unstructured":"Floros T, Tarhini AA. Anticancer cytokines: biology and clinical effects of interferon-alpha2, interleukin (IL)-2, IL-15, IL-21, and IL-12. Semin Oncol. 2015;42(4):539\u201348.","journal-title":"Semin Oncol"},{"issue":"8B","key":"777_CR3","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1111\/j.1582-4934.2008.00412.x","volume":"13","author":"A Labbe","year":"2009","unstructured":"Labbe A, et al. IL-12 immunotherapy of murine leukaemia: comparison of systemic versus gene modified cell therapy. J Cell Mol Med. 2009;13(8B):1962\u201376.","journal-title":"J Cell Mol Med"},{"issue":"11","key":"777_CR4","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1158\/2326-6066.CIR-13-0208","volume":"2","author":"ME Nelles","year":"2014","unstructured":"Nelles ME, et al. Murine splenic CD4(+) T cells, induced by innate immune cell interactions and secreted factors, develop antileukemia cytotoxicity. Cancer Immunol Res. 2014;2(11):1113\u201324.","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"777_CR5","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/gt.2014.10","volume":"21","author":"JC Morris","year":"2014","unstructured":"Morris JC, et al. Vaccination with tumor cells expressing IL-15 and IL-15Ralpha inhibits murine breast and prostate cancer. Gene Ther. 2014;21(4):393\u2013401.","journal-title":"Gene Ther"},{"issue":"1","key":"777_CR6","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/imr.12644","volume":"283","author":"ME Raeber","year":"2018","unstructured":"Raeber ME, et al. The role of cytokines in T-cell memory in health and disease. Immunol Rev. 2018;283(1):176\u201393.","journal-title":"Immunol Rev"},{"issue":"3","key":"777_CR7","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1074\/jbc.M508624200","volume":"281","author":"E Mortier","year":"2006","unstructured":"Mortier E, et al. Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta\/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins. J Biol Chem. 2006;281(3):1612\u20139.","journal-title":"J Biol Chem"},{"key":"777_CR8","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3389\/fimmu.2013.00450","volume":"4","author":"A Marcais","year":"2013","unstructured":"Marcais A, et al. Regulation of mouse NK cell development and function by cytokines. Front Immunol. 2013;4:450.","journal-title":"Front Immunol"},{"issue":"9","key":"777_CR9","doi-asserted-by":"publisher","first-page":"6072","DOI":"10.4049\/jimmunol.177.9.6072","volume":"177","author":"TA Stoklasek","year":"2006","unstructured":"Stoklasek TA, Schluns KS, Lefrancois L. Combined IL-15\/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. J Immunol. 2006;177(9):6072\u201380.","journal-title":"J Immunol"},{"issue":"4","key":"777_CR10","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.4049\/jimmunol.180.4.2099","volume":"180","author":"S Dubois","year":"2008","unstructured":"Dubois S, et al. Preassociation of IL-15 with IL-15R alpha-IgG1-fc enhances its activity on proliferation of NK and CD8+\/CD44high T cells and its antitumor action. J Immunol. 2008;180(4):2099\u2013106.","journal-title":"J Immunol"},{"issue":"8","key":"777_CR11","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1158\/0008-5472.CAN-08-0045","volume":"68","author":"M Epardaud","year":"2008","unstructured":"Epardaud M, et al. Interleukin-15\/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. Cancer Res. 2008;68(8):2972\u201383.","journal-title":"Cancer Res"},{"issue":"9","key":"777_CR12","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1158\/1535-7163.MCT-09-0275","volume":"8","author":"A Bessard","year":"2009","unstructured":"Bessard A, et al. High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer. Mol Cancer Ther. 2009;8(9):2736\u201345.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"777_CR13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1158\/2326-6066.CIR-15-0093-T","volume":"4","author":"PR Rhode","year":"2016","unstructured":"Rhode PR, et al. Comparison of the Superagonist complex, ALT-803, to IL15 as Cancer Immunotherapeutics in animal models. Cancer Immunol Res. 2016;4(1):49\u201360.","journal-title":"Cancer Immunol Res"},{"key":"777_CR14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.pharmthera.2016.10.012","volume":"170","author":"JM Bergh Van den","year":"2017","unstructured":"Van den Bergh JM, et al. IL-15 receptor alpha as the magic wand to boost the success of IL-15 antitumor therapies: the upswing of IL-15 transpresentation. Pharmacol Ther. 2017;170:73\u20139.","journal-title":"Pharmacol Ther"},{"key":"777_CR15","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.cyto.2017.08.004","volume":"99","author":"AT Waickman","year":"2017","unstructured":"Waickman AT, et al. CD4 effector T cell differentiation is controlled by IL-15 that is expressed and presented in trans. Cytokine. 2017;99:266\u201374.","journal-title":"Cytokine"},{"issue":"2","key":"777_CR16","doi-asserted-by":"crossref","first-page":"641","DOI":"10.4049\/jimmunol.121.2.641","volume":"121","author":"CJ Paige","year":"1978","unstructured":"Paige CJ, Kincade PW, Ralph P. Murine B cell leukemia line with inducible surface immunoglobulin expression. J Immunol. 1978;121(2):641\u20137.","journal-title":"J Immunol"},{"issue":"1","key":"777_CR17","doi-asserted-by":"publisher","first-page":"277","DOI":"10.4049\/jimmunol.167.1.277","volume":"167","author":"X Wei","year":"2001","unstructured":"Wei X, et al. The sushi domain of soluble IL-15 receptor alpha is essential for binding IL-15 and inhibiting inflammatory and allogenic responses in vitro and in vivo. J Immunol. 2001;167(1):277\u201382.","journal-title":"J Immunol"},{"issue":"7","key":"777_CR18","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1074\/jbc.M705725200","volume":"283","author":"C Bergamaschi","year":"2008","unstructured":"Bergamaschi C, et al. Intracellular interaction of interleukin-15 with its receptor alpha during production leads to mutual stabilization and increased bioactivity. J Biol Chem. 2008;283(7):4189\u201399.","journal-title":"J Biol Chem"},{"key":"777_CR19","doi-asserted-by":"publisher","first-page":"e1792","DOI":"10.1038\/cddis.2015.162","volume":"6","author":"Y Jiang","year":"2015","unstructured":"Jiang Y, Li Y, Zhu B. T-cell exhaustion in the tumor microenvironment. Cell Death Dis. 2015;6:e1792.","journal-title":"Cell Death Dis"},{"issue":"1","key":"777_CR20","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1182\/blood-2017-07-740993","volume":"131","author":"ZY Xu-Monette","year":"2018","unstructured":"Xu-Monette ZY, Zhou J, Young KH. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood. 2018;131(1):68\u201383.","journal-title":"Blood"},{"key":"777_CR21","doi-asserted-by":"publisher","first-page":"14601","DOI":"10.1038\/ncomms14601","volume":"8","author":"ML Robinette","year":"2017","unstructured":"Robinette ML, et al. IL-15 sustains IL-7R-independent ILC2 and ILC3 development. Nat Commun. 2017;8:14601.","journal-title":"Nat Commun"},{"key":"777_CR22","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0065-230X(08)00408-9","volume":"101","author":"M Terabe","year":"2008","unstructured":"Terabe M, Berzofsky JA. The role of NKT cells in tumor immunity. Adv Cancer Res. 2008;101:277\u2013348.","journal-title":"Adv Cancer Res"},{"issue":"15","key":"777_CR23","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1182\/bloodadvances.2018020388","volume":"2","author":"B Mundy-Bosse","year":"2018","unstructured":"Mundy-Bosse B, et al. Highly cytotoxic natural killer cells are associated with poor prognosis in patients with cutaneous T-cell lymphoma. Blood Adv. 2018;2(15):1818\u201327.","journal-title":"Blood Adv"},{"key":"777_CR24","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3389\/fimmu.2013.00190","volume":"4","author":"DO Adeegbe","year":"2013","unstructured":"Adeegbe DO, Nishikawa H. Natural and induced T regulatory cells in cancer. Front Immunol. 2013;4:190.","journal-title":"Front Immunol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0777-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0777-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0777-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T06:57:38Z","timestamp":1695538658000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0777-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["777"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0777-8","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"4 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All experimental procedures were approved by the Animal Care Committee of the Ontario Cancer Institute.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"355"}}